Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akeso, Inc. (HK:9926) has announced a new phase II clinical study titled ‘A Phase II Clinical Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer.’ The study aims to evaluate the safety and efficacy of the drug combination AK130 and AK112 in treating advanced pancreatic cancer, a condition with limited treatment options. This study is significant as it explores new therapeutic avenues for a challenging disease.
The intervention involves two experimental drugs, AK130 and AK112, tested both in combination and as monotherapy. These drugs are designed to target cancer cells, potentially offering a new treatment pathway for patients with advanced pancreatic cancer.
The study follows a randomized, parallel assignment model without masking, focusing on treatment as its primary purpose. This design allows for a clear comparison of the drug combination’s effects against monotherapy.
The study is set to begin recruitment on August 3, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was also on August 3, 2025, indicating the study’s preparation phase.
For investors, this study could impact Akeso’s stock performance positively if the results show promise, given the high unmet need in pancreatic cancer treatment. The study’s progress could also influence investor sentiment and market dynamics, especially if competitors are not pursuing similar avenues.
The study is currently in the preparation phase, with further details available on the ClinicalTrials portal.